Skip to Content

A biotech startup based on U of M anticancer research aims to begin clinical trials for a new immunological drug that could fight brain cancer.

"OX2 Therapeutics Inc., co-founded by Masonic Cancer Center, University of Minnesota researchers Michael Olin and Dr. Chris Moertel, is working on a therapy based on the pair’s discovery that a certain kind of protein associated with cancer blocks the effectiveness of vaccines now being developed to treat brain cancer tumors (known as glioblastomas), as well as other kinds of tumors."

See the full story in Twin Cities Business.

Unit: 
Office for Technology Commercialization